RMC-9805 manufacturers
- RMC-9805
-
- $1.00
-
2026-09-18
- CAS:2922732-54-3
- Min. Order: 1kg
- Purity: 99
- Supply Ability: 15KG
- Zoldonrasib
-
- $129.00
-
2026-08-13
- CAS:2922732-54-3
- Purity: 98.22%
- Supply Ability: 10g
- RMC-9805
-
-
2026-06-30
- CAS:2922732-54-3
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 1000
|
| | RMC-9805 Basic information |
| Product Name: | RMC-9805 | | Synonyms: | RMI-5921;KRAS G12D inhibitor 18|||KRAS G12D IN 18;(2S)-2-Cyclopentyl-2-((S)-7-((2R,3R)-3-cyclopropyl-1-methylaziridine-2-carbonyl)-2,7-diazaspiro[4.4]nonan-2-yl)-N-((22S,63S,4S)-12-(5-(4-cyclopropylpiperazin-1-yl)-2-((S)-1-methoxyethyl)pyridin-3-yl)-10,10-dimethyl-5,7-dioxo-11-(2,2,2-trifluoroethyl)-61,62,63,64,65,66-hexahydro-11H-8-oxa-2(4,2)-morpholina-1(5,3)-indola-6(1,3)-pyridazinacycloundecaphane-4-yl)acetamide;(2S)-2-cyclopentyl-2-[(5S)-7-[(2R,3R)-3-cyclopropyl-1-methylaziridine-2-carbonyl]-2,7-diazaspiro[4.4]nonan-2-yl]-N-[(6S,8S,14S)-21-[5-(4-cyclopropylpiperazin-1-yl)-2-[(1S)-1-methoxyethyl]pyridin-3-yl]-18,18-dimethyl-9,15-dioxo-22-(2,2,2-trifluoroethyl)-5,16-dioxa-2,10,22,28-tetraazapentacyclo[18.5.2.12,?.11?,1?.023,2?]nonacosa-1(26),20,23(27),24-tetraen-8-yl]acetamide;KRAS G12D inhibitor 18, 10 mM in DMSO;RMC-9850;(2S)-2-Cyclopentyl-2-[(5S)-2-[(2R,3R)-3-cyclopropyl-1-methylaziridine-2-carbonyl]-2,7-diazaspiro[4.4]nonan-7-yl]-N-[(6S,8S,14S)-21-[5-(4-cyclopropylpiperazin-1-yl)-2-[(1S)-1-methoxyethyl]pyridin-3-yl]-18,18-dimethyl-9,15-dioxo-22-(2,2,2-trifluoroethyl)-5,16-dioxa-2,10,22,28-tetrazapentacyclo[18.5.2.12,6.110,14.023,27]nonacosa-1(26),20,23(27),24-tetraen-8-yl]acetamide;Zoldonrasib/RMI-5921 | | CAS: | 2922732-54-3 | | MF: | C63H88F3N11O7 | | MW: | 1168.44 | | EINECS: | | | Product Categories: | API | | Mol File: | 2922732-54-3.mol |  |
| | RMC-9805 Chemical Properties |
| density | 1.45±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | | pka | 13.79±0.40(predicted) | | form | Solid | | color | White to off-white |
| | RMC-9805 Usage And Synthesis |
| Uses | RMC-9805 (KRAS G12D inhibitor 18) is a potent and orally active KRAS G12D inhibitor. RMC-9805 induces apoptosis in KRAS G12D mutant cancer cells. RMC-9805 has the potential for the research of KRAS G12D mutant cancer[1][2]. | | in vivo | RMC-9805 (100 mg/kg; po; once daily for 4-8 days) shows antitumor activity in KRAS G12D xenograft models[2].
| Animal Model: | Mice[2] | | Dosage: | 100 mg/kg | | Administration: | PO; once daily for 4-8 days | | Result: | Decreased the level of myeloid cells, such as mMDSC, gMDSC, M2 TAMS, increased the level of cytotoxic T cells including CD3e+, CD4+, CD8+ T cells. |
| | IC 50 | KRAS(G12D) | | References | [1] BLAKE JAMES F, et al. Preparation of peptide-linked macrocyclic dipeptides as Ras inhibitors.World Intellectual Property Organization, WO2023060253 A1 2023-04-13
[2] Knox,J et al.RMC-9805, a first-in-class, mutant-selective, covalent and orally bioavailable KRASG12D(ON) inhibitor, promotes cancer-associated neoantigen recognition and synergizes with immunotherapy in preclinical models.Cancer Res1 April 2023; 83 (7_Supplement): 3475 |
| | RMC-9805 Preparation Products And Raw materials |
|